Moderna stock price outlook: Is the rally overextended?
Moderna shares continue to rally, gaining more than 38% since June 26, as positive momentum following the company's updated drug pipeline continues to support investor sentiment.
Since our previous analysis, there have been no significant corporate developments related to Moderna. Investors remain focused on the updated pipeline presented during Moderna's Science Day, which continues to support confidence in the company's long-term growth prospects.
As a result, the stock's recent performance has been driven primarily by technical factors following several years of heavy selling pressure and oversold conditions.

Moderna bulls now need to defend $80
The previously identified upside scenario has now been confirmed, with Moderna shares breaking into the $75.50–80 liquidity zone and holding above it.The breakout significantly improved the technical picture and confirmed that bullish momentum remains intact.
However, after six consecutive trading sessions of gains, the probability of a short-term pullback has increased noticeably. In the event of a correction, the $75.50–80 range, which previously acted as strong resistance, is likely to become the first major support zone.
The primary technical risk remains the RSI (14), which has moved into overbought territory. This increases the likelihood that the rally could lose momentum before extending higher.
Earnings will be Moderna's next major catalyst
The next key event for Moderna will be its earnings report on July 30. Following the stock's strong recovery, investors will be looking not only for improving financial results but also for updated guidance on the company's mRNA pipeline and future product development.
The earnings release is likely to determine whether the current rally receives fundamental confirmation. Strong results and optimistic guidance could support further upside, while any signs of slowing momentum may trigger a correction.
Latest Moderna News
- Forex
- Crypto